



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|-----------------------------|------------------------|
| 10/783,128 | 02/20/2004 | James McSwiggen | MBHB04-105 (400.146) | 2611 |
| 65778 7590 09/20/2007 MCDONNELL, BOEHNEN, HULBERT AND BERGHOFF, LLP 300 SOUTH WACKER DRIVE SUITE 3100 CHICAGO, IL 60606 | | | EXAMINER CHONG, KIMBERLY | |
| | | | ART UNIT 1635 | PAPER NUMBER |
| | | | MAIL DATE 09/20/2007 | DELIVERY MODE PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | | | |
|------------------------------|--------------------------------------|---|--|
| Office Action Summary | Application No. 10/783,128 | Applicant(s) MCSWIGGEN, JAMES | |
| | Examiner Kimberly Chong | Art Unit 1635 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 July 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3,13-21 and 30-35 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,3,13-21,30-35 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>07/05/07</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Status of Application/Amendment/Claims

Applicant's response filed 07/06/2007 has been considered. Rejections and/or objections not reiterated from the previous office action mailed 01/05/2007 are hereby withdrawn. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

With entry of the amendment filed on 07/06/2006, claims 1, 3, 13-21 and 30-31, 33-35 are pending in the application. Applicant has canceled claims 2, 4-12, 22-29 and 32.

Priority

Applicant does not receive the benefit of the earlier filed applications because the prior applications do not provide adequate support for the claims of the instant application and thus applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120.

The instant application does not receive the benefit of any of the earlier filed priority documents because the instantly cited invention of a molecule targeted to a human huntingtin (HD) nucleotide sequence wherein about 100% of nucleotide positions in one or both strands of said molecule are chemically modified, is not supported by the specification or claims of the priority applications.

In the Remarks filed 07/06/2007, Applicant points to support in the provisional application 60/363,124, from which priority application PCT/US03/05028 depends, for a chemically modified nucleic acid molecule wherein both the sense and antisense strands are 100% modified. Applicant points to sequences 27653 and 27658 as being comprising 100 % of chemical modifications. Sequences 27653 and 27658 as disclosed are only 85% modified and further are not even disclosed as a duplex. Furthermore, there are no sequences in Table 1 or shown in Figures 3-10 that comprise 100% chemical modifications. Moreover, there are no nucleic acid sequences comprising a sense and an antisense strand wherein both strands are 100% modified in Table I, pages 55-57 nor in Figures 3-10 as pointed out by Applicant. A further review of the disclosure of application 60/363,124 fails to find nucleic acid sequences comprising a sense and an antisense strand wherein both strands are 100% modified, as required by the instant claims. Support is found in priority application PCT/US03/05028. If Applicant still believes the prior application 60/363,124 provides support then applicant must point, with particularity, to where such support can be found in the specification of the prior application.

Thus, the claims are accorded a priority date of 02/20/2003, the filing date of the priority application PCT/US03/05028.

Information Disclosure Statement

The submission of the Information Disclosure Statement on 07/05/2007 is in compliance with 37 CFR 19.7. The information disclosure statement has been considered by the examiner and signed copies have been placed in the file.

Specification

The substitute specification filed 07/05/2007 has not been entered because it does not conform to 37 CFR 1.125(b) and (c) because: the statement as to a lack of new matter under 37 CFR 1.125(b) is missing.

New Claim Objections and Rejections

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 33-35 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 3, 13-21 and 30-31 of copending Application No. 10/824,036, in view of Rana, T. (of record).

This is a provisional obviousness-type double patenting rejection.

An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim not is patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

The instant claims are drawn to a chemically modified nucleic acid molecule comprising a distinct sense strand and an antisense strand wherein 1, 2 or 3 of the purine nucleotides present in the sense strand are 2'-O-methyl purine nucleotides, wherein one or both strands include 3' overhangs and wherein the 3' overhangs are chemically modified.

Claims 1, 3, 13-21 and 30-32 of copending Application 10/824,036 are drawn to a siRNA molecule wherein each strand of said molecule is about 18 to about 27 nucleotides in length and wherein one strand is complementary to a human HD nucleotide sequence and wherein one or more pyrimidine nucleotides present in one or both strands of said siRNA molecule is a 2'-deoxy-2'-fluoro pyrimidine modification. The claims of copending Application 10/824,036 are further drawn to such siRNA molecule wherein the double stranded nucleic acid molecule comprises one or more ribonucleotides, wherein one or more pyrimidine nucleotides in the sense or antisense strand are 2'-O-methyl or 2'-O-deoxy-2'-fluoro, wherein one or more purine nucleotides in the sense or antisense strand are 2'-deoxy or 2'-O-methyl, wherein the sense strand

comprises a terminal cap moiety at the 5'-end, the 3'-end or both, wherein the antisense strand comprises a terminal phosphorothioate internucleotide linkage, wherein the 5' end includes a terminal 5'-phosphate and further drawn to a pharmaceutical composition comprising said double stranded nucleic acid.

The claims of copending application 10/824,036 fail to disclose such siRNA wherein about 100% of nucleotide positions in one or both strands of said siRNA molecule are chemically modified. Rana teach that such siRNA can be modified at internal residues such that properties like increased chemical stability and nuclease resistance are improved without compromising the RNA interference activity (see paragraph 0029). Rana teach that the RNAi mechanism does not require 2'-OH chemical groups and these groups could be replaced with such nucleotides such as 2'-deoxy, 2'-O methyl and 2'-fluoro and the will still efficiently induce RNAi in human cells. Rana teach the siRNA can comprise one or more chemical modifications in the sugar or nucleobase groups and teach the siRNA can comprise any combination of two or more modifications (see paragraphs 0036-0040). Rana teach that sense and/or antisense strands of such siRNA can comprise 100% of chemically modified nucleotides and specifically teach such siRNA comprising 100% of chemically modified nucleotides are stable (see Figure 12).

Therefore, it would have been obvious to make a siRNA molecule comprising chemical modifications in all nucleotides in one or both strands. One of ordinary skill would have been motivated to incorporate chemical modifications in all nucleotides in one or both strands because Rana teach that such siRNA comprising chemical

modifications enhance the molecules chemical stability and nuclease resistance and further such modifications are important for in vivo applications, particularly human therapeutics.

Claim Rejections - 35 USC § 103

Applicant's arguments filed 07/06/2007 regarding the rejection of record under 35 U.S.C. 103(a) that are considered relevant to the instant claims and newly applied rejection under 35 U.S.C. 103(a) will be discussed below.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 3, 13-15, 18-21 and 30-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hayden et al. (of record), Rana (of record), Hammond et al. (of record), Bass et al (of record), Matulic-Adamic (of record) and evidenced by Caplen (of record).

The instant claims are drawn to a chemically modified molecule comprising a distinct sense strand and an antisense strand, each strand having one or more pyrimidine or purine nucleotides, wherein each strand is about 18 to about 27 nucleotides in length and the antisense strand comprises a nucleotide sequence of about 18 to about 27 nucleotides that is complementary to a human HD nucleotide

Art Unit: 1635

sequence having SEQ ID No. 3578 and about 50 to 100% of nucleotide positions in one or both strands of said molecule are chemically modified. The instant claims are further drawn to such molecule wherein the molecule comprises one or more ribonucleotides, wherein one or more pyrimidine nucleotides in the sense or antisense strand are 2'-O-methyl or 2'-O-deoxy-2'-fluoro, wherein one or more purine nucleotides in the sense or antisense strand are 2'-deoxy or 2'-O-methyl, wherein the sense strand comprises a terminal cap moiety at the 5'-end, the 3'-end or both, wherein the antisense strand comprises a terminal phosphorothioate internucleotide linkage, wherein the 5' end includes a terminal 5'-phosphate, wherein one or both strands comprise a 3' overhang that is chemically modified and further drawn to a pharmaceutical composition comprising said double stranded nucleic acid.

Hayden et al. teach an antisense compound targeted to a human HD gene (see paragraph 0082). Hayden et al. teach human Huntington's Disease is a neurodegenerative disease caused by a mutation in the huntingtin protein that leads to neuronal cell death and further teach inhibition of a gene encoding a huntingtin protein leads to inhibition of apoptosis of neuronal cells. Hayden et al. further teach the antisense compound can comprise sugar, nucleobase and internucleoside modifications to increase the biological stability of said compound and enhance cellular uptake and further increase the antisense compounds affinity for the target sequence. (see paragraph 0087). Hayden et al. do not teach a double-stranded nucleic acid molecule targeted to a HD gene and further do not teach the nucleotides of the sense and antisense strands comprise chemical modifications.

Hammond et al. teach two methods for silencing specific genes: antisense and RNA interference. Hammond et al. teach that although antisense methods are straightforward techniques for probing gene function, the methods have suffered from "...questionable specificity and incomplete efficacy." (see page 110, column 1). Hammond et al. further teach " "...dsRNAs have been shown to inhibit gene expression in a sequence-specific manner" and further "RNAi is a potent method, requiring only a few molecules of dsRNA per cell to silence expression." Similarly, Bass et al. states that RNA interference using siRNA has "...repeatedly proven itself to be more robust than antisense techniques: It works more often, and typically decreases expression of a gene to lower levels, or eliminates it entirely." Bass et al. points out that siRNAs are effective at targeting transgenes as well as naturally occurring endogenous genes (see page 428). Bass et al. further states "...siRNAs are effective at concentrations that are several orders of magnitude below the concentrations typically used in antisense experiments."

Rana teach siRNA molecules which are 10-50 nucleotides in length and preferably 18-25 nucleotides in length that are capable of directing or mediating RNA interference (see paragraph 0070). Rana teach such siRNA molecules are comprised of separate sense and antisense strands wherein the siRNA comprises a sequence that is complementary to a target mRNA to direct target specific RNA interference. Rana further teach the siRNA comprises a 5' phosphate group attached to the hydroxyl group of the 5' sugar (see paragraph 0059). Rana teach that such siRNA can be modified at internal residues such that properties such as chemical stability and nuclease

Art Unit: 1635

resistance are improved without compromising the RNA interference activity and teach the siRNA can comprise 3' overhangs on one or both strands (see paragraph 0029).

Rana teach that the RNAi mechanism does not require 2'-OH chemical groups and these groups could be replaced with such nucleotides such as 2'-deoxy, 2'-O methyl and 2'-fluoro and the siRNA was still able to efficiently induce RNAi in human cells.

Rana teach the 3' terminal end or the 5' terminal end of the siRNA can be modified with such groups as peptides, cross linkers or organic compounds (see paragraph 0033).

Rana teach pharmaceutical compositions comprising such siRNA (see paragraph 207).

Rana teach the siRNA can comprise one or more chemical modifications in the sugar or nucleobase groups and teach the siRNA can comprise any combination of two or more modifications (see paragraphs 0036-0040). Rana teach that sense and/or antisense strands of such siRNA can comprise at least 100% of chemically modified nucleotides and specifically teach such siRNA comprising 100% of chemically modified nucleotides are stable (see Figure 12).

Matulic-Adamic et al. teach double stranded structures comprising abasic terminal cap moieties that provide resistance to degradation (see column 2, lines 44-55 and column 3 lines 1-68).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to make a siRNA molecule, as taught by Hammond et al., Bass et al. and Rana to target a gene encoding HD, as taught by Hayden et al. Further it would have been obvious for one of ordinary skill in the art to make siRNA nucleic acid

Art Unit: 1635

molecules with chemical modifications in the sense or antisense strand, as taught by Rana.

One would have been motivated to use a siRNA targeted to a HD gene and inhibit gene expression because Hayden et al. teach human HD proteins are involved in neurodegenerative diseases and inhibition of HD expression inhibits apoptosis of neuronal cells (see paragraph 0007). One would have been motivated to use a siRNA targeted to HD instead of an antisense because it was well known at the time the invention was made that dsRNA molecules are efficient molecules to target and decrease expression of a target gene given that Hammond et al. teach using dsRNA to inhibit gene expression is more sequence specific than using antisense methodologies and RNAi using dsRNA is a more potent method requiring only a few molecules of dsRNA per cell and given that Bass et al. teach siRNA are more potent than antisense compounds. Although Hayden et al. do not specifically teach targeting a human HD gene having GenBank Accession No. NM_002111 (SEQ ID No. 3578), it would have been obvious to target this gene given that Hayden et al. details the advantages of target a human HD gene and inhibiting expression from such a gene to treat numerous neurodegenerative disorders associated with the overexpression from said gene. Further, because Rana teach the RNAi mechanism does not require 2'-OH chemical groups, one of skill in the art would have been motivated to incorporate 2'-O-methyl, 2'-deoxy or 2'-deoxy-2'-fluoro chemical modifications in one or both strands as specifically taught by Rana to increase the duplex stability. One would therefore be motivated to chemically enhance the siRNAs resistance to nucleases while preserving or maximizing

Art Unit: 1635

its activity in order to most effectively target the desired gene. Matulic-Adamic et al. provide motivation to make a siRNA with terminal cap moieties to provide resistance and degradation given that Matulic-Adamic et al. teach double stranded structures comprising terminal cap moieties.

The motivation to chemically modify siRNA is further evidenced by Caplen (Expert Opin Biol Ther, 2003 Jul, 3(4), pp. 575-86), who points out that, "Many of the problems associated with developing RNAi as an effective therapeutic are the same as encountered with previous gene therapy approaches. The key issues of delivering nucleic acids to the required tissue and cell type, while ensuring an appropriate level of efficacy with minimum toxicity induced by the vector system..." (see page 581). As evidenced by Caplen, RNA interference encounters similar problems as other nucleic acid based therapies and therefore, one would be motivated to incorporate each of the above-mentioned modifications in an attempt to enhance delivery of any of the sequence specific oligonucleotide therapeutics.

Finally, one would have a reasonable expectation of success because Hayden et al. teach antisense molecules can be targeted to a human HD gene and regulate gene expression, Hammond et al. and Bass et al. teach that of the two methods used for silencing gene function, RNAi using dsRNA is more potent and sequence specific than antisense. One would have had a reasonable expectation of success at introducing chemical modifications wherein about 100% of the nucleotides were modified given that Rana specifically teach such siRNA are more stable and such siRNA are capable of eliciting RNA interference activity in cells. Further, one would have a reasonable

Art Unit: 1635

expectation of success because chemical modifications of an oligonucleotide, adding stability and specificity to oligonucleotides were known in the art at the time of the invention was made. Additionally, one would expect such modifications would benefit siRNAs because such modifications, such used by Matulic-Adamic, had been shown to benefit antisense or ribozymes.

Thus in the absence of evidence to the contrary, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art at the time the invention.

Claims 1, 3, 13-21 and 30-35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Davidson et al. (of record), Rana (of record), Matulic-Adamic (of record) and evidenced by Caplen (of record).

The instant claims are drawn to a chemically modified nucleic acid molecules as recited above.

Davidson et al. teach siRNA directed to a human HD nucleotides sequence. Davidson et al. teach siRNA are ideal compounds to target mutant alleles such as found in HD (see paragraphs 0043 and 0052). Davidson et al. teach such siRNA are less than 30 nucleotides and preferably 19 to 25 nucleotides in length and comprise two strands (see paragraph 0144). Davidson et al. specifically teach such siRNA inhibition of the expression of a huntingtin protein (see Example 4 and Figure 15). Davidson et al. does not teach such siRNA comprising chemical modifications of the sense or antisense strand wherein about 100% of nucleotide positions in one or both strands of said molecule are chemically modified.

Rana teach siRNA molecules which are 10-50 nucleotides in length and preferably 18-25 nucleotides in length that are capable of directing or mediating RNA interference (see paragraph 0070). Rana teach such siRNA molecules are comprised of separate sense and antisense strands wherein the siRNA comprises a sequence that is complementary to a target mRNA to direct target specific RNA interference. Rana further teach the siRNA comprises a 5' phosphate group attached to the hydroxyl group of the 5' sugar (see paragraph 0059). Rana teach that such siRNA can be modified at internal residues such that properties such as chemical stability and nuclease resistance are improved without compromising the RNA interference activity (see paragraph 0029). Rana teach that the RNAi mechanism does not require 2'-OH chemical groups and these groups could be replaced with such nucleotides such as 2'-deoxy, 2'-O methyl and 2'-fluoro and phosphorothioate and the siRNA was still able to efficiently induce RNAi in human cells. One would therefore be motivated to chemically enhance the siRNAs resistance to nucleases while preserving or maximizing its activity in order to most effectively target the desired gene Rana teach the 3' terminal end or the 5' terminal end of the siRNA can be modified with such groups as peptides, cross linkers or organic compounds (see paragraph 0033). Rana teach pharmaceutical compositions comprising such siRNA (see paragraph 207). Rana teach the siRNA can comprise one or more chemical modifications in the sugar or nucleobase groups and teach the siRNA can comprise any combination of two or more modifications (see paragraphs 0036-0040). Rana teach that sense and/or antisense strands of such siRNA can comprise at least 100% of chemically modified nucleotides and specifically

teach such siRNA comprising 100% of chemically modified nucleotides are stable (see Figure 12).

Matulic-Adamic et al. teach double stranded structures comprising abasic terminal cap moieties that provide resistance to degradation (see column 2, lines 44-55 and column 3 lines 1-68).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate such chemical modifications as taught by Rana into the siRNA targeted to a HD nucleotide sequence, as taught by Davidson et al. Matulic-Adamic et al. provide motivation to make a siRNA with terminal cap moieties to provide resistance and degradation given that Matulic-Adamic et al. teach double stranded structures comprising terminal cap moieties and incorporate of such modifications increases the molecules stability and nuclease resistance.

Although Davidson et al. do not specifically teach targeting a human HD gene having GenBank Accession No. NM_002111 (SEQ ID No. 3578), it would have been obvious to target this gene given that Hayden et al. details the advantages of target a human HD gene and inhibiting expression from such a gene to treat numerous neurodegenerative disorders associated with the overexpression from said gene. One would have been motivated to incorporate chemical modifications because Rana teach the RNAi mechanism does not require 2'-OH chemical groups, one of skill in the art would have been motivated to incorporate 2'-O-methyl, 2'-deoxy or 2'-deoxy-2'-fluoro chemical modifications in one or both strands as specifically taught by Rana to increase the duplex stability. The motivation to chemically modify siRNA is further evidenced by

Caplen (Expert Opin Biol Ther, 2003 Jul, 3(4), pp. 575-86), who points out that, "Many of the problems associated with developing RNAi as an effective therapeutic are the same as encountered with previous gene therapy approaches. The key issues of delivering nucleic acids to the required tissue and cell type, while ensuring an appropriate level of efficacy with minimum toxicity induced by the vector system..." (see page 581). As evidenced by Caplen, RNA interference encounters similar problems as other nucleic acid based therapies and therefore, one would be motivated to incorporate each of the above-mentioned modifications in an attempt to enhance delivery of any of the sequence specific oligonucleotide therapeutics.

Finally, one would have a reasonable expectation of success given that Davidson et al. teach inhibition of expression for a HD gene using a siRNA targeted to a HD nucleotide sequence and further one would have had a reasonable expectation of success at introducing chemical modifications wherein about 100% of the nucleotides were modified given that Rana specifically teach such siRNA are more stable and such siRNA are capable of eliciting RNA interference activity in cells. Further, one would have a reasonable expectation of success because chemical modifications of siRNA, adding stability and specificity to oligonucleotides were known in the art at the time of the invention was made.

Thus in the absence of evidence to the contrary, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art at the time the invention.

Response to Applicant's Arguments

Applicants submit Rana, T and Davidson et al. are not prior art because the claims are accorded a priority date of 3/11/2002. As discussed above, the instant claims are accorded a priority date of 02/20/2003 and therefore both Rana and Davidson et al. are available as prior art.

Applicants argue none of the references alone or in combination render obvious the presently claimed nucleic acid molecule because the cited references do not teach or suggest all of the claim elements. As stated in the new claim rejections above it would have been obvious to one of ordinary skill in the art at the time the invention was made to make a siRNA molecule, as taught by Hammond et al. to target a gene encoding HD, as taught by Hayden et al.

With regard to applicant's assertion that antisense and ribozyme art is not analogous art to siRNA and should not be used for an obviousness type rejection, applicant's argument appears to focus entirely on the mechanism of action of each molecule and appears to ignore the basic fact that each of the inhibitory molecules are made of nucleotides which are susceptible to nuclease degradation in cells, regardless of the type of structure of the nucleic acid. As such, one of skill in the art would clearly recognize that if these types of chemical modifications improved an antisense or ribozymes nuclease resistance and stability in cells, then these chemical modifications would work to improve the nuclease resistance and stability of similar nucleic acids i.e. siRNA and therefore it would have been obvious to incorporate such modifications into siRNA.

Art Unit: 1635

Applicant argues Matulic-Adamic et al. is not pertinent to the problem addressed by the presently claimed compounds because Matulic-Adamic et al. is drawn to a ribozyme which is unrelated to RNAi. Matulic-Adamic et al. is relied upon to teach obvious chemical modifications to any nucleic acid molecule, such as a siRNA, for the purpose of increasing nuclease resistance, stability and target specificity: modifications that would be obvious to one of skill in the art to incorporate into a nucleic acid molecule used to target a specific gene for inhibition of expression.

Therefore, as discussed above, in the absence of evidence to the contrary, the invention, as a whole would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made.

Re: Double Patenting

Acknowledgement is made of Applicant's request that the rejection be held in abeyance until allowable matter is indicated in the instant claims, therefore the rejection of claims 1, 3, 13-21 and 30-32 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 3, 13-21 and 30-31 of copending Application No. 10/824,036, in view of Rana, T. (US 2005/0020521) is maintained.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP

Art Unit: 1635

§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kimberly Chong whose telephone number is 571-272-3111. The examiner can normally be reached Monday thru Friday between 7-4 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Schultz can be reached at 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service

Art Unit: 1635

center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

KC
Examiner
Art Unit 1635

/Sean McGarry/
Primary examiner
AU 1635